IP Library › Granted Patent US 10,478,447
Granted Patent B2
US 10,478,447 · App. 15/882,832 · Granted Nov 19, 2019

Antiviral supplement formulations

Inventors: Kenneth E. Phillips (Tulsa, OK); Cynthia A. Winning (Parker, CO)
Assignee: Vymedic, LLC
A61K31/7028A61K31/145A61K31/185A61K31/198A61K31/221A61K31/375A61K31/44A61K31/4415A61K31/455A61K31/513A61K31/7048A61K45/06Y02A50/465
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,478,447
App. No.
15/882,832
Granted
Nov 19, 2019
Kind
B2
Abstract

The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.

Claims (22)

1. A method of treating a viral infection in a subject in need thereof comprising administering to the subject a dosage form comprising a therapeutically effective amount of a composition comprising a lysine in a single dose range of from about 1,000 mg to about 5,000 mg, an ascorbic compound, a flavonoid glycoside, wherein the flavonoid glycoside comprises hesperidin and rutin, a threonine, a taurine and a pyridoxine, and wherein the viral infection is selected from the group consisting of an influenza virus infection and a non-polio enterovirus infection.

2. The method of claim 1 , wherein the influenza virus infection is selected from the group consisting of an influenza A, influenza B, and influenza C virus infection.

3. The method of claim 1 , wherein the dosage form is selected from the group consisting of powder, capsule, lozenge, troche, tablet, liquid, or caplet.

4. The method of claim 1 , wherein the dosage form is a solid dosage form.

5. The method of claim 1 , wherein the dosage form is a chewable form.

6. The method of claim 1 , wherein the lysine is selected from L-lysine, L-lysine monohydrochloride, L-lysine dihydrochloride, L-lysine succinate, L-lysine glutamate, and L-lysine orotate.

7. The method of claim 1 , wherein the ascorbic compound is selected from one or more of ascorbic acid, calcium ascorbate, magnesium ascorbate, potassium ascorbate, sodium ascorbate, manganese ascorbate, zinc ascorbate, iron ascorbate, copper ascorbate, boron ascorbate, molybdenum ascorbate, chromium ascorbate, ascorbyl palmitate, ascorbyl arachidonate, ascorbyl stearate, ascorbyl linoleate, ascorbyl linoleneate, and ascorbyl oleate.

8. The method of claim 1 , wherein the flavonoid glycoside comprises hesperidin and rutin in about a 1:1 weight ratio.

9. The method of claim 1 , wherein the composition comprises L-lysine monohydrochloride, ascorbic acid, calcium ascorbate, niacinamide ascorbate, ascorbyl palmitate, hesperidin, rutin, pyridoxine hydrochloride, threonine, and taurine.

10. The method of claim 9 , wherein the composition further comprises calcium ascorbate, niacinamide ascorbate, and ascorbyl palmitate.

11. A method to decrease the severity or duration of symptoms of a viral infection in a subject in need thereof comprising administering to the subject a dosage form comprising a therapeutically effective amount of a composition comprising a lysine in a single dose range of from about 1,000 mg to about 5,000 mg, an ascorbic compound, a flavonoid glycoside, wherein the flavonoid glycoside comprises hesperidin and rutin, a threonine, a taurine and a pyridoxine, wherein the viral infection is selected from the group consisting of an influenza virus infection and a non-polio enterovirus infection.

12. The method of claim 11 , wherein the influenza virus infection is selected from the group consisting of influenza A, influenza B, and influenza C virus infection.

13. The method of claim 11 , wherein the dosage form is selected from the group consisting of powder, capsule, lozenge, troche, tablet, liquid, or caplet.

14. The method of claim 11 , wherein the dosage form is a solid dosage form.

15. The method of claim 11 , wherein the dosage form is a chewable form.

16. The method of claim 11 , wherein the lysine is selected from L-lysine, L-lysine monohydrochloride, L-lysine dihydrochloride, L-lysine succinate, L-lysine glutamate, and L-lysine orotate.

17. The method of claim 11 , wherein the ascorbic compound is selected from one or more of ascorbic acid, calcium ascorbate, magnesium ascorbate, potassium ascorbate, sodium ascorbate, manganese ascorbate, zinc ascorbate, iron ascorbate, copper ascorbate, boron ascorbate, molybdenum ascorbate, chromium ascorbate, ascorbyl palmitate, ascorbyl arachidonate, ascorbyl stearate, ascorbyl linoleate, ascorbyl linoleneate, and ascorbyl oleate.

18. The method of claim 11 , wherein the flavonoid glycoside comprises hesperidin and rutin in about a 1:1 weight ratio.

19. The method of claim 11 , wherein the composition comprises L-lysine monohydrochloride, ascorbic acid, calcium ascorbate, niacinamide ascorbate, ascorbyl palmitate, hesperidin, rutin, pyridoxine hydrochloride, threonine, and taurine.

20. The method of claim 19 , wherein the composition further comprises calcium ascorbate, niacinamide ascorbate, and ascorbyl palmitate.

21. The method of claim 11 , wherein the symptoms are selected from the group consisting of runny nose, sneezing, stuffy nose, body aches, fatigue, fever, cough, sore throat, and headache.

22. The method of claim 21 , wherein the administering is performed at the first sign of flu-like illness indicated by one or more of the symptoms, at intervals selected from the group consisting of every four waking hours, every six waking hours, and twice a day, until symptoms are resolved.

Assignments (2)
CHANGE OF NAME Recorded Oct 27, 2023
From: VYMEDIC, LLC
To: VYMEDIC INC.
Reel/Frame 065476/0736 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2018
From: PHILLIPS, KENNETH E.; WINNING, CYNTHIA A.
To: VYMEDIC, LLC
Reel/Frame 047426/0782 →
Continuity (4)
Division 14681817 · Apr 8, 2015
Continuation 12609120 · Oct 30, 2009
Provisional Application 61111234 · Nov 4, 2008
Related Publication 20180256618A1 · Sep 13, 2018
Cited By (1)
US 12,702,677